VivoSim Labs Plans To Develop Rat Liver Model To Complement Existing NAMkind Human Liver Platform And Expand Its Liver Toxicology Capabilities
VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced plans to
VivoSim is building a new rat liver model to go along with their human liver tool, which helps them test if medicines are safe. This shows the company is growing what they can do, which could help them serve more customers.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.